IBJNews

Lilly to focus on cancer, diabetes in China, CEO says

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.

“We are increasing our investments in every aspect of our business in China,” Lechleiter told reporters at a briefing in Beijing.

The company’s China sales force doubled in the last three years, to more than 3,600 in the country, he said. And company sales grew 25 percent in China in 2011, higher than the industry average.

Diabetes treatments have been one of the biggest drivers of Lilly’s growth in China. The company opened a diabetes research center in Shanghai last year.

“Our goal is to be the fastest growing pharmaceutical company in China,” Lechleiter said.

Drugmakers may face pressure on margins in China because the government is vowing to cut drug prices in an overhaul of the country’s health-care system aimed at trimming the cost of caring for an aging population.

Lilly also hopes to make progress in China with non-diabetes and cancer drugs. The company is confident its Cialis drug for treating erectile dysfunction can overtake Pfizer’s Viagra in China, Lilly China president Eric Baclet said. Lilly introduced Cialis in China in 2009.

“On beating Viagra, in our quest for leadership in some of these China cities, we feel very confident about this,” Baclet told reporters in Beijing.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT